Garcia Marino received 57,482 derivative securities in AgomAb Therapeutics NV on Sep 11, 2026, leaving the director with 57,482 derivative securities. For investors, the transaction represents about 100.0% of Garcia Marino’s resulting derivative-securities holding, identifying the full position created by the award.
Key Highlights
- The transaction took place on Sep 11, 2026.
- The filing identifies transaction code A for the award.
- The transaction represents about 100.0% of Garcia Marino’s resulting derivative-securities holding.
Garcia Marino received 57,482 derivative securities of AgomAb Therapeutics NV, leaving the director with 57,482 derivative securities after the award. The transaction involved AgomAb Therapeutics NV, identified as AGMB.
AgomAb Derivative Securities Award
The award was recorded under transaction code A. Garcia Marino serves as a director of AgomAb Therapeutics NV. The transaction concerns derivative securities. The reported post-transaction position contains 57,482 derivative securities.
Resulting Position Identified
The awarded amount and the resulting position are both stated at 57,482 derivative securities. The filing states that the transaction represents about 100.0% of Garcia Marino’s resulting derivative-securities holding. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: How many AgomAb derivative securities did Garcia Marino receive?
A: Garcia Marino received 57,482 derivative securities of AgomAb Therapeutics NV on September 11, 2026. Following the transaction, the filing reported the same 57,482 derivative securities as Garcia Marino’s resulting holding.
Q: What does Garcia Marino’s AgomAb insider transaction involve?
A: The filing reports an award of 57,482 derivative securities in AgomAb Therapeutics NV for Garcia Marino. It identifies the transaction with code A.
Q: When did Garcia Marino receive the AgomAb derivative securities?
A: Garcia Marino received the 57,482 derivative securities on Sep 11, 2026. The transaction represented about 100.0% of the resulting derivative-securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.